Summary

This randomized, phase 2 trial evaluated PGG beta-glucan, a novel immune modulator, in combination with bevacizumab and carboplatin/paclitaxel as first-line treatment for patients with stage IV non–small cell lung cancer. Though not statistically significant, the results for the primary and secondary end points favor the PGG beta-glucan–treated group and warrant further study of PGG beta-glucan as an adjunct to bevacizumab-containing chemotherapy regimens.